potentially fatal arrhythmia, known as torsade de pointes mammals has varying effects on action potential duration (TdP). The incidence of TdP in patients treated with and may prolong or shorten it [18] . Changes in the quinidine whose spectrum of effects includes K-channel expression patterns of ion channels may also occur in blockade, has been estimated to range between 2.0 and disease and there are different patterns, as well, in normal 8.8% [1] [2] [3] [4] . For D,L-sotalol, an incidence ranging between males and females ( Table 2 ). 1.8% and 4.8% has been described [5] [6] [7] . A similar A reduction in net outward current and / or an increase in incidence has been seen for newer 'class III' agents, e.g.
inward current can potentially facilitate the development of dofetilide [8] and ibutilide [9] . early afterdepolarizations. Early afterdepolarizations occur Recently, it has become apparent that not only antipreferentially in M cells and Purkinje cells due to reactivaarrhythmic drugs but a variety of non-anti-arrhythmic tion of the L-type calcium current and / or activation of the agents may aggravate and / or provoke TdP [10] [11] [12] . The sodium-calcium exchange current during the action ponumber of non-anti-arrhythmic drugs reported to induce tential plateau [19] [20] [21] [22] . When accompanied by a marked QT interval prolongation with or without TdP continues to increase in dispersion of repolarization there is increased increase ( Table 1) . As many as 50 clinically available or likelihood that early afterdepolarization-induced extrastill investigational non-cardiovascular drugs and carsystoles will trigger re-entry and TdP (Figs. 3-5) [23] [24] [25] [26] . diovascular non-anti-arrhythmic drugs have been impliMost of our present understanding of TdP is based on the cated. A number of drugs, both old and new, have either study of drugs which block I . Virtually all drugs that Kr been withdrawn from the market (e.g. prenylamine, have been shown to increase the QT interval, incorporate terodiline, sertindole, astemizole and in some countries I blockade in their spectrum of effects. However, any Kr terfenadine and cisapride) or have had their sale restricted drug which reduces net repolarising currents may pose a (e.g. cisapride, some fluoroquinilones, pimozide and some risk for inducing this arrhythmia. other neuroleptics, terfenadine and halofantrine). Of conElectrotonic cell-to-cell coupling influences the dispercern is the interval, usually measured in years, from the sion of repolarization. If myocardial cells with intrinsically marketing of these drugs to initial recognition of their different action potential duration are well coupled, elecassociation with QT interval prolongation and / or TdP.
trotonic current flow attenuates the differences in action potential duration. Thus, in the intact left ventricular wall, differences in action potential duration are smaller than in 3. Mechanisms of QT prolongation and TdP myocytes or tissues isolated from epicardial, endocardial and M cell layers. In transmural sections of the ventricular Prolongation of the QT interval on the electrocarwall (wedge preparation), the dispersion in action potential diogram is caused by prolongation of the action potentials duration averaged 51 ms at a cycle length of 1000 ms [27] . of ventricular myocytes, brought about by a reduction of
In the intact left ventricular wall of open-chest dogs, the outward currents and / or enhancement of inward currents transmural differences in refractory periods or activationduring phase 2 and 3 of the action potential. Fig. 1 shows recovery intervals were even smaller, in the order of 20-30 the ionic basis of the cardiac action potential. There is an ms [28] [29] [30] . Selection of anaesthetic agents and extracelluintrinsic transmural heterogeneity in the density of the lar recording techniques also influence the measurement of various ion channels that determine ventricular repolarizadispersion of repolarization in in vivo studies under tion. Block or activation of these channels have different baseline, and even more so under long QT conditions [26] . effects on the action potential duration of the four cell It is likely that macroscopic tissue resistance, caused by types: Purkinje cells, subendocardial myocytes, midchanges in fiber direction across the ventricular wall, myocardial M cells and subepicardial myocytes, as decontributes to dispersion in repolarization. Partial uncoupicted in Fig. 2 . It is important to note that there are also pling due to fibrosis (as in ageing or hypertrophy) may important species and tissue differences in these currents.
further unmask intrinsic differences in action potential Thus, in isolated guinea pig, sheep and dog myocardium, duration. both I and I are present, whilst in cat, rabbit and man, The development of early afterdepolarizations and TdP
Kr Ks
I is the predominant current [13] . Moreover there usually occurs with drugs that block I . For obvious Kr Kr remains controversy over the relative roles of I and I in reasons, the frequency with which a given drug produces Kr Ks ventricular repolarization in individual species, such as the QT interval prolongation and / or TdP during its uncontroldog (compare Refs. [14, 15] [15] [16] [17] . The transient outward current which blocks HERG [31] , is one out of 120 000 patients I contributes to the phase 1 notch of the action potential treated [32] while for D,L-sotalol, a markedly higher to and is present in man and dog, but is poorly expressed in incidence has been reported (see above). This likely guinea pig. Blockage of I in myocardium from large reflects the fact that cisapride more often is given to a Note: These data derive from what is effectively a non-controlled review of the literature. Hence, some of the drugs listed have profound effects on QT prolongation and on induction of torsades de pointes, and others have minor effects whose documentation is in some instances questionable and not clearly related to the drug given as opposed to an inter-current condition. The list is presented, then, to indicate the diversity of drugs and effects cited. However, the reader is urged to review the literature on any of these drugs before making decisions that relate to their administration. patients with normal hearts than sotalol whose use is confined to patients with cardiac arrhythmias. In the congenital long QT syndrome, mutations in HERG have been found at many sites, and, thus far, no correlation has been established between phenotype and the extent of I Kr dysfunction [33] . The precise reasons for the different effects of I blockers are unknown but many factors Kr modulate the effects of drugs that block I ( Table 2 ).
Kr
One factor of particular importance for the genesis of TdP is a particular predisposition of individual patients. Recently, it has been demonstrated that in patients who developed TdP secondary to class III agents, drug-induced QTc prolongation was more marked than in patients without TdP and, furthermore, it was not related to the dose of the drug [34] . Thus, patients with TdP showed an abnormal response following exposure to the drug. The reason for such a behaviour is not clear.
The presence of a forme fruste of a long QT syndrome congenital long QT syndrome [35] . However, it cannot be excluded that yet unknown subtle genetic defects may set the stage for the abnormal QT prolongation and TdP. Such subtle genetic defects have been shown to result in a low penetrance in phenotypic expression which might imply a lowered threshold for the development of abnormal QT prolongation and TdP upon challenge with a specific drug [36] . A reduced repolarization reserve [37] may underlie acquired abnormal QT prolongation and TdP. This concept emphasises that the occurrence of TdP secondary to a repolarization prolonging drug is a patient-specific response. This hypothesis is supported by reports of patients who developed additional episodes of TdP during sub- [ [38] [39] [40] [41] . 'Patient-specific response' does not necessarily Kr most marked at low heart rates and decreases at higher heart rates (reverse use-dependence) [74] .
Gender QT interval is longer in women than in men [63] . TdP occurs more frequently in women [6, 75] . Female rabbits have less I than male rabbits [76] .
Hypertrophy and heart failure The action potential is prolonged and both the transient outward current and the delayed rectifier current are reduced [18] . [81] . In rabbits, alpha-adrenergic stimulation potentiates the effect of I blockers [57] .
Reduced repolarization reserve, Patient-specific increased propensity to development 'formes frustes' of the congenital of abnormal QT prolongation and TdP [37] . long QT syndrome Non-symptomatic carriers of mutated genes for Na or K channels may be more susceptible to drugs that prolong repolarization [35, 36] .
a TdP, torsade de pointes; LQT, long QT syndrome.
mean that the individual patient will always show abnor-4. Detecting drug-induced effects on repolarization mal QT prolongation and TdP during exposure to repolarization prolonging stimuli. This becomes obvious when
The risk of drug-induced TdP arrhythmias raises a considering the highly variable intervals between the dilemma of early detection of the effects of any new initiation of drug therapy and occurrence of TdP reported chemical entity on cardiac ventricular repolarization. The in the literature.
impressive list of drugs, already on the market or still (studied acutely or in culture), isolated tissues, and the isolated intact (Langendorff-perfused) heart. oocytes present limitations in measuring rapidly activating voltage-gated channels [44] . Furthermore, the IC50 for under development that have been reported to adversely drug effects may be falsely overestimated due to the prolong repolarization, makes it imperative to investigate relatively large volume of lipophilic material in the oocyte any new chemical entity for this potential side effect [44] . Mammalian recombinant expression systems are before its first use in man. Preclinical screening should be increasingly used, as they do not share these limitations of conducted in vitro and in vivo using the parent compound, oocytes and can be evaluated at physiological temperature. its enantiomers when the new chemical entity is chirally Most studies have used human embryonic kidney cells active, and the major metabolites, once these have been (HEK293), mouse fibroblasts (C cells) and Chinese hamidentified. In any research project, the models used should ster ovary (CHO) cells, all of which have relatively little facilitate the testing of the hypotheses put forward. A endogenous voltage-gated channel activity. When such number of models having variable advantages and limitamodels are used for drug studies, the effects of at least four tions are available (Table 3 ). Fig. 6 shows a proposed different concentrations encompassing a 100-1000 fold flow-chart of studies designed to assess the potential of range should be evaluated and the IC50 of both, the parent drugs to prolong repolarization.
compound and its metabolites should be precisely determined. Overall, the results from such studies should not 4.1. In vitro models be considered in isolation as an absolute criterion for deciding whether or not to continue further development. effects in human subjects (e.g. astemizole or cisapride). In addition, a range of cycle lengths should be studied. For both, these studies and the more complex models, below, attention should be paid to gender, given the demonstration both, in human subjects [6] and animal models such as the rabbit [49] , of the greater QT-prolonging and arrhythmogenic effects of I blocking agents in females.
For screening large numbers of compounds, the Langendorff-perfused guinea pig or rabbit heart studied with electrogram or monophasic action potential recording techniques also gives consistent information on I blockKr ing drugs when compared to standard compounds [50, 51] . Excess prolongation of repolarization in this model indicates potential problems caused by the drug. Failure to see excess action potential prolongation does not, however, provide complete security in excluding the risk of TdP. For example, in this setting one is unaware of the potential effects of metabolites. Effects of the new chemical entities on sinus rhythm should be carefully screened as K channel blockers frequently produce slight bradycardia. TdP-like polymorphic ventricular tachyarrhythmias can be induced in the isolated rabbit heart by reproducing conditions and circumstances that are clinically known to be associated with an increased propensity to develop TdP (i.e. hypokalemia and bradycardia) [51] [52] [53] . In vivo models can be studied using multi-lead ECG taining the animal in the same position each time it is studied. Equations to correct QT duration for heart rate can [45] or I [46] and / or decreasing I [47] ) would not be be used, although the accuracy of the correction algorithms Ca Ks identified as potentially proarrhythmic unless the latter varies in different animal models [56] . More information currents are included as well.
can be obtained using QT-RR plots in the absence and Whereas the disaggregated cell is an ideal model for presence of various drug dosages, or by pacing the heart at studying ion currents, its action potential duration varia constant rate. Telemetric recordings can provide a useful ability even when paced at a constant cycle length, reduces adjunct in intact animal studies. its utility for studying action potentials [48] . It is here that
Carlsson and co-workers [21, 55, 57] have shown that isolated tissue studies serve an important purpose. In clofilium, almokalant, dofetilide and sematilide may induce studying isolated tissues with microelectrodes, the species marked QT prolongation and TdP-like polymorphic venselected should be one for which adequate data exist that tricular tachycardia in alpha-chloralose anaesthetised rabdemonstrate similarity with human material. The species bits concomitantly treated with an infusion of the alpha-1-most frequently used are dog, rabbit, and guinea pig. For agonist methoxamine. A conscious dog model with TdP isolated tissue studies, canine mid-myocardium and Purlike polymorphic ventricular tachycardia has been dekinje fibers appear most susceptible to the effects of I scribed by Weissenburger and co-workers in which Kr block. Endo-and epicardial muscle should be studied as bradycardia and hypokalemia were combined [58, 59] . well to ensure that the potential for dispersion is explored Bradycardia was achieved by chemically or electrically [26] . Any one of several 'pure' I blockers can be used for induced complete AV block whereas hypokalemia was kr comparison, and comparators may be chosen for which induced over a period of weeks using high doses of clinical studies have already demonstrated significant diuretics. Vos et al. [60] recently described a canine model with chronic AV block exposed to D-sotalol where different Hence, the model shows promise in discriminating the pacing modes were used to mimic sequences of short / proarrhythmic effects of various I blocking drugs.
Kr long / short intervals. Such sequences are typically obImportant to the understanding of the strengths and served in patients with acquired LQTS but have recently limitations of these models is the demonstration by Vos and been shown to play a role in the genesis of TdP in patients associates [61] that the AV block induces ventricular with the congenital LQTS as well. Of interest is the hypertrophy. Hence, arrhythmias induced by drugs in these demonstration by Vos et al. [60] that anti-arrhythmic drugs animals impact on our expectations for the normal heart having known proarrhythmic effects induce significant QT largely by inference, while directly impacting on the prolongation and torsade de pointes in this model, and the relationship between hypertrophic hearts and drugs. Moredemonstration by Sosunov et al. [54] in the same model over, it should be noted that while these models provide that an antipsychotic drug with I blocking properties has information that tends to increase or decrease one's Kr a much lower QT prolonging or proarrhythmic effect. understanding of the spectrum of drug effect, none will the future development of a new chemical entity with demonstrated effects on ventricular repolarization, perhaps most important is the indication for the compound and the benefit it provides versus the risk it confers. Other factors may include the availability of alternative therapies with less risk and the margin of safety suggested by the preclinical data.
Clinical assessment of drug effects on repolarization

Phase I /II studies
In early Phase I / II studies, safety considerations should be directed primarily at the early identification of a change in repolarization, usually QT or QTc prolongation, which might herald the risk of pro-arrhythmia when the drug is administered more widely to a larger population of patients during Phase III studies [62, 63] . Important questions during the early clinical phases of drug development include: (1) What electrocardiographic repolarization signal should be measured? (2) What threshold QTc signal is of concern, and what are the clinical implications of a small yet statistically significant QTc prolongation? (3) Since QTc quantifies a complex relationship between the duration of ventricular repolarization and heart rate, what accelerate heart rate? and (4) Which heart rate correction is preferred when evaluating the effects of a drug on venprovide complete security with regard to drug effects in tricular repolarization? human subjects.
Phase I clinical studies should be placebo-controlled In light of the above, we stress the importance of not trials that involve healthy volunteers who, however, may defining a single, standardised and uniform method for not be representative of the general population that will be preclinical screening of the effects of drug effects on exposed to the drug should it be approved and marketed cardiac repolarization. Among the various methods avail-(unless the drug is an anti-histaminic or similar comable, none has demonstrated a predictive value that makes pound). Due to the increased risk of TdP in females, these it clearly superior to others. In vivo methods introduce an studies should include sufficient numbers of females (with intrinsic degree of variability and need for QT correction appropriate contraceptive precautions for women at risk of in relation to the heart rate. This may introduce an error of pregnancy). If there is any likelihood that the new comovercorrection or undercorrection depending on the equapound will be used in children, they should also be studied tion used and the species. On the other hand, in vivo at the appropriate time during the clinical development of methods explore the potential effects of not only the parent the drug. The selection of children and decisions regarding compound but also of active metabolites (the exception the ages of those studied will depend on a number of being metabolites unique to man which must be studied in ethical and personal issues, among them the potential for their own right in vivo and in vitro).
comprehension and co-operation, as well as parent / guarFinally, the potential risk / benefit ratio of any new dian involvement and approval. chemical entity must be taken into account when a
The drug dosing should incorporate a reasonable dosedecision is made based on preclinical data. These precliniresponse range, with a short-term upper dosing level as cal data should be correlated with any clinical data high as possible during careful safety monitoring. Plasma available. Among the factors to be considered regarding serum concentrations of the parent drug and relevant active metabolites should be monitored to obtain peak and trough values based on the known pharmacokinetics and the reached. Several serial 12-lead ECGs should be obtained at impossible but raises the question whether the U wave baseline and during follow-up after drug administration. In should be included in the QT interval measurement. addition to recordings at regular intervals, the timing of Although this will result in a reading of excessive QT these recordings should consider carefully the pharinterval duration, such an interpretation may be appropriate macokinetic parameters and the concentrations of the with regard to certain drugs. parent drug as well as those of active metabolites.
From a safety point of view, there is no easy answer to Studies involving QT interval measurement should the question as to how many subjects should be studied always be conducted under placebo control and the meaduring Phase I / II trials. The sample size for Phase I / II surement should be processed by a laboratory experienced studies is usually based on the need to characterise the in good clinical practice standards and electrocarclinical pharmacology of the drug with preliminary considdiography. Twelve-lead ECGs are preferable, as are digital erations of efficacy but with an anticipation that safety recordings and storage. The measurement of the QT issues related to a major increase in QTc will most likely interval should always include the assessment of T wave be identified. However, many issues arise here. For morphology changes and appearance and / or disappearance example, (1) there may be a small, yet significant increase of abnormal TU patterns. Since such patterns may occur in in mean QTc. Whether this is meaningful, suggesting a only some of the electrocardiographic leads, the analysis of potentially serious safety problem if the drug is suball 12 leads is preferable.
sequently approved for administration to a very large There is no clear consensus on methods for the measurepopulation, is controversial. (2) The number of subjects to ment of the QT interval but in each study, the same be studied during Phase I / II trials for the purpose of safety method should be used. Multiple measurements in each is difficult to predict. It is suggested that if no adverse ECG (e.g. three to five beats of each lead) are necessary to repolarization abnormalities are observed during precliniimprove precision. The distribution of the maxima and cal testing, then a minimum of 100 subjects should be minima of the QT interval among all 12 ECG leads is not rigorously studied in early Phase I / II testing; if some stable and the selection of only one lead for measurement minor yet consistent repolarization abnormalities are unmay create a selection bias. Measurement on computer covered during preclinical or clinical testing, then 200 or screen seems to provide the highest precision. more subjects should be studied [62] . (3) In Phase I / II Because of the lack of experience with algorithms for trials, any individual who develops a prolonged QTc automatic QT interval measurement, evaluation by a interval after drug administration that is generally considqualified electrocardiographer should be mandatory. With ered to be a so-called outlier, takes on special significance. manual measurement, a substantial proportion of the Such an outlier may reflect a true drug-related effect, i.e. electrocardiograms (if not all) should be measured by two an important signal; or the long QTc value may simply independent observers. represent a random variation unrelated to drug administraSince the duration of the QT interval is heart rate tion. This issue requires careful attention, such that the dependent, the evaluation of QT interval changes must subject should be rechallenged with the same drug to always incorporate the consideration of the underlying elucidate whether the effect on QTc is reproducible. If so, changes in heart rate. Various heart rate correction formulae then further dose-response testing is indicated. have been proposed (e.g. Bazett, Fridericia, Framingham, If early Phase I / II studies demonstrate no QTc safety etc.) [64, 65] . While these formulae are appropriate in concerns, then expanded Phase I / II testing is appropriate. standard clinical practice, e.g. for the diagnosis of long QT If the age range of the initial study population was syndrome, their use in the evaluation of drug related QT restricted, a broader age spectrum should be included in changes may lead to either false positive or false negative further studies. It is essential to include subjects with findings. Non-linear regression analysis of the QT / RR common clinical cardiac disorders, such as patients with interval data points is preferable (including the assessment coronary heart disease, hypertension, and congestive heart of confidence intervals) as this documents QT interval failure in these late Phase I / II studies if such patients are changes independent of the underlying heart rate [66] .
likely to receive the drug when it is marketed. Repeated QT dispersion as determined from the maximum minus doses may need to be administered to further substantiate minimum QT intervals on the 12-lead ECG has not yet the QTc safety of the drug if any questions had been raised been adequately validated as a risk indicator of pro-arduring earlier testing. If the drug is metabolised by the rhythmia. Increased QT dispersion, therefore is currently hepatic P450 enzyme system, drug-interaction studies with not recommended as a parameter to assess drug-induced appropriate inhibitors(s) of the isoform involved (for alteration in ventricular repolarization. Only very substanexample ketoconazole and / or erythromycin in case of the tial values of QT dispersion (e.g. .100 ms) seem to be a cytochrome 3A4 isoform) are indicated, with particular reliable indicator of repolarisation abnormalities.
attention to circulating drug levels and QTc effects [67, 68] . The presence of pathological U waves complicates the During this phase of testing, high doses of the drug (as determination of the precise QT interval duration. Often, high as ten to 50 times those recommend) may be the U wave overlaps with the T wave to such a degree that cautiously administered. determination of the end of the T wave is not only A meaningful QT / QTc prolongation during Phase I / II studies is difficult to define in general terms. Due to the efficacy-orientated and their results may be strongly insmall number of subjects tested in these early studies, even fluenced by inclusion and exclusion criteria. Therefore, it a small change may be important. It has not been settled is important to consider how representative the clinical whether a small but reproducible QTc prolongation in trial population of the ultimate target population is. It is Phase I / II studies is indicative of a possible serious QTchelpful to include in late Phase II and Phase III studies related pro-arrhythmia when the drug is utilized by subjects with common clinical cardiac disorders, such as thousands or millions of people after market approval. A patients with coronary heart disease, hypertension, and single outlier with drug-induced QTc prolongation .500 congestive heart failure if such patients are likely to ms or an increase by 60 ms or more from baseline after receive the drug when it is marketed. For the same reasons, rechallenge during Phase I / II studies may be taken more the inclusion of patients with other co-morbidities and seriously than a significant increase in the mean value.
co-medications should also be considered. Similarly, a statistically significant increase in mean QTc as small as 6 ms between baseline and maximal drug effect 5.3. Post-marketing surveillance at the planned (recommended) drug dose may be important [69] . Estimation of the importance depends on risk-benefit Demonstration of both short-and long-term safety and considerations for the intended use of the drug and the efficacy is increasingly necessary to obtain approval of availability of alternative therapies with lesser risk. For new drugs. Any conclusion that a drug is 'safe' should be example, if a drug is effective in treating oncological reserved until post-marketing surveillance data are redisorders, then some degree of QTc prolongation may be viewed. Only when large numbers of patients are treated, acceptable. On the other hand, if a drug will be marketed many of whom will be taking multiple medications, who to treat allergic rhinitis in otherwise healthy people, then have different co-morbidities, and who are subject to other even minor QTc prolongation may not be acceptable, conditions that were not represented in the original clinical especially if alternative drugs without QTc-prolonging trial population, will adverse effects become manifest that effects are available.
were otherwise not recognized, appreciated or expected. If small but significant drug-related repolarization effects are observed during Phase I / II studies, additional preclinical studies are needed to clarify the effect and to 6. Regulatory perspectives evaluate a possible underlying mechanism. For example, if a small degree of QTc prolongation is identified in early There has been an increasing regulatory concern about clinical studies, specific in-vitro expression studies if not drug-induced QT prolongation and TdP. Recommendations previously performed, can help to determine if the drug has and guidelines for the pre-clinical and clinical screening any influence on the I ion channel, an ion channel which and assessment of any new drug with regard to its potential Kr has frequently been implicated in drug-induced repolarizaelectrophysiological effects are urgently needed. In Detion abnormalities. Dose-response studies can be quickly cember 1997, the Committee for Proprietary Medicinal carried out in the in-vitro setting.
Products (CPMP) of the European Agency for the EvaluaIt is likely that in the future a spectrum of non-invasive tion of Medicinal Products issued a document entitled electrocardiographic repolarization parameters will be utiPoints to Consider: The assessment of the potential for QT lized in drug evaluation since digital ECGs are now interval prolongation by non-cardiovascular medicinal available. Quantitative computerised processing and analyproducts [62] . This CPMP document was a strong signal to sis of digital ECGs include QT / U intervals, QT / RR drug developers that the problem of QT interval prolongarelationships, T-wave morphology on ECG and / or VCG, tion and / or TdP by non-cardiovascular drugs is now a very spatial heterogeneity of repolarization, and dynamic beatsignificant one and, thus, requires careful scrutiny and to-beat T-wave changes (T-wave lability and microvolt research efforts for any compound undergoing develop-T-wave alternans). These measurements are likely to ment. supplement and possibly replace the manual QTc measureBased on experience with previously approved comments of today. Such analytic techniques may identify pounds, questions arose as to whether there had been any drug-related repolarization effects more accurately and signals during the development of these drugs that may reliably than current methods, thus improving the safety have pointed to the possibility of their proarrhythmic screening of drugs in Phase I / II clinical studies.
effects, and why such effects had not been detected during preclinical and clinical development programs. Another 5.2. Phase III studies question was whether one can rely on clinical trials alone to identify the risk of proarrhythmia or whether additional If findings from Phase I / II studies are indicative of a or alternative strategies should be used to facilitate predicrisk, recording ECGs in all the patients in Phase III studies tion of this risk. should be seriously considered in order to better characterIn the present environment, it is perhaps unlikely that ize the QT safety of the drug during its post-marketing any non-cardiovascular or non-anti-arrhythmic drug associclinical use. However, these Phase III studies are highly ated with clinically documented TdP during its clinical evaluation will reach a regulatory submission stage unless This regulatory management of drugs which prolong the it offers unique and otherwise unavailable clinical benefits.
QT interval is only one aspect of an overall strategy aimed Rather than the frequency of TdP, the regulatory auat containing or minimising risk. In the final analysis, thorities are most often left with evaluation of the clinical whether or not a patient will benefit from detailed prescribsignificance of the degree and frequency of QT prolongaing information depends on the patient and his / her pretion observed in the clinical trials without having observed scribing physician. Experience regarding physician comany cases of TdP. Another problem is the evaluation of pliance with prescribing restrictions and monitoring recases of sudden death in patients taking any of several quirements to date is not encouraging. In a number of non-cardiac drugs known to prolong repolarization. In surveys relating to terfenadine [70, 71] and cisapride [72], these cases, it is frequently difficult if not impossible to there was significant, inappropriate prescription of these create a link between QT prolongation and the mechanism drugs to patients at increased risk. In addition, monitoring of subsequent death if no intervening TdP has been requirements such as baseline and / or periodic ECGs had observed.
been ignored in many cases. Regulatory authorities have Apart from an ever-increasing number of 'proarrhythmic been sensitized to issues such as how and to what extent non-cardiovascular' drugs, regulatory concerns have been there is likely to be compliance with complex prescribing intensified because of the increasing size of the population information and monitoring requirements. These considthat may be at risk. This applies to the elderly who erations are attaining increased importance in the apfrequently receive multiple drugs with the potential for provability of new drugs and in reviewing the safety interaction, and to patients with cardiac, renal, hepatic or profiles of older drugs. other predisposing diseases which may increase the risk of abnormal drug elimination and metabolism and create the potential for increased susceptibility to proarrhythmia.
7. Conclusions Patients with myocardial hypertrophy or heart failure with or without abnormalities in repolarization represent other There is increasing awareness that drugs used for nonhigh risk groups, and in all such groups, the independent anti-arrhythmic and non-cardiovascular indications may risk conferred by female gender must be considered. have significant effects on repolarization and may cause From the regulatory perspective, it is vitally important serious ventricular tachyarrhythmias under specific circumthat the distinction between drug-induced and spontaneous stances. For new drugs, the effects on the QT interval QT interval prolongation is carefully made. If this is not should be identified and, if possible, quantified during done, a harmless drug may be inappropriately labelled and pre-clinical and clinical development. Post-marketing surdenied to needy patients. On the other hand, when repolariveillance data of approved and marketed drugs provide zation abnormalities go unrecognized, the public may be additional important information about drug safety. In placed at unnecessary risk. The overall risk-benefit assessaddition, clinicians and patients should be aware of this ment of a new drug that prolongs the QT interval depends risk of prolongation of repolarization and take precautions on consideration of (1) the frequency and magnitude of the to further minimize it. Academic centres should be encour-QT changes observed and related adverse events detected aged to develop new technologies for objective assessment in the clinical programme, (2) the safety risks presented by of the repolarisation patterns including the diagnosis of the the drug relative to its therapeutic potential, and (3) the presence of pathological U waves. availability of clinically effective alternatives with a more favourable safety profile.
The labelling implications for a drug that prolongs the Appendix A QT interval are considerable. Detailed consideration of the above factors should enable a final decision to be made Other speakers in the sessions and chairs of the workregarding the approvability of a new medicinal product, shops who contributed significantly and have to be considand where appropriate, the conditions for clinical use to be ered as co-authors (in alphabetical order): Jean Thierry included in its Summary of Product Characteristics (preBarbey, MD; Jacques Barhanin, MD, PhD; Jerry L. scribing information). New York, USA; Jurgen Armbrecht, MD, Hoffmann-La
